Johnson & Johnson MedTech (NYSE: JNJ) today announced the launch of its Inhance Intact shoulder arthroplasty instrumentation system.
The company developed the complete instrumentation system specifically for subscapularis-sparing total shoulder arthroplasty (TSA). It aims to enable surgeons to replace a damaged shoulder joint while keeping the shoulder muscle intact.
According to J&J MedTech — one of the largest medtech companies in the world — more than 100,000 people in the U.S. undergo TSA each year. It treats degenerative conditions like osteoarthritis and rotator cuff tears. While effective, the company says the traditional deltopectoral approach often requires the detachment of the subscapularis tendon. As a result, patients often face up to six weeks of post-operative immobilization, the company said.
Tim Schmid, J&J MedTech’s EVP and worldwide chair, will be among top medtech leaders discussing M&A strategy at DeviceTalks West next week — Oct. 15–16, 2025 in Santa Clara, California. Register here. (Here’s a 25% off discount code: MD25OFF)
Inhance Intact’s tissue-sparing approach allows surgeons to perform TSA with enhanced joint visualization. This approach also enables patient shoulder movement as early as one day post-operation. Faster rehabilitation also supports the trend toward minimally invasive care and makes Inhance Intact “ideal” for ambulatory surgery centers (ASCs).
Johnson & Johnson MedTech says the comprehensive system aims to meet the evolving demands of TSA through use with the Inhance Shoulder System. It features a stemless implant, 43 purpose-built instruments and TruMatch personalized solutions. The system supports anatomic precision, bone preservation and surgical accuracy through patient-specific 3D planning.
(MDO’s Medtech Big 100 Special Report takes a deep look at the world’s 100 largest medical device companies, including Johnson & Johnson MedTech. Visit here for a free download.)
The company says the full procedural solution enables consistent results across a broad range of care settings. It unveiled the technology earlier this year and says it’s now available in the U.S.
“The introduction of Inhance Intact marks an important step forward in advancing shoulder care through thoughtful, clinically driven innovation,” said Sharrolyn Josse, worldwide president, Joint Reconstruction, Johnson & Johnson MedTech. “By offering solutions to surgeons that allow their patients to have immediate mobility, we’re expanding what’s possible for surgeons and strengthening an approach designed to improve outcomes, accelerate recovery, and support the shift to outpatient care.”
